Abstract:Ye Zhang, 1 Xiaoli Tan, 2 Shiyu Hu, 3 Zhifang Cui, 4 Wenyu Chen 2 1 Department of General Medicine, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China; 2 Department of Respiratory Medicine, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China; 3 Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Jiaxing, Zhejiang, People's Republic of China; 4 Department of Respiratory Medicine, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence: Wenyu Chen, Department of Respiratory Medicine, Affiliated Hospital of Jiaxing University, No. 1882, Zhonghuan South Road, Nanhu District, Jiaxing City, Zhejiang Province, 314001, People's Republic of China, Email Purpose: Chronic obstructive pulmonary disease (COPD) concurrent with respiratory failure (RF) is devastating, and may result in death and disability. Systemic immune-inflammation index (SII) is a new prognostic biomarker linked to unfavorable outcomes of acute coronary syndrome, ischemic stroke, and heart failure. Nonetheless, its role in COPD is rarely investigated. Consequently, this study intends to assess the accuracy of SII in predicting the prognosis of COPD. Patients and Methods: The clinical information was retrospectively acquired from the Medical Information Mart for Intensive Care-IV database. The outcomes encompassed the incidence of RF and mortality. The relationship between different SII and outcomes was examined utilizing the Cox proportional-hazards model and restricted cubic splines. Kaplan-Meier analysis was employed for all-cause mortality. Results: The present study incorporated 1653 patients. During hospitalization, 697 patients (42.2%) developed RF, and 169 patients (10.2%) died. And 637 patients (38.5%) died during long-term follow-up. Higher SII increased the risk of RF (RF: HR: 1.19, 95% CI 1.12– 1.28, P< 0.001), in-hospital mortality (HR: 1.22, 95% CI 1.07– 1.39, P=0.003), and long-term follow-up mortality (HR: 1.12, 95% CI 1.05– 1.19, P< 0.001). Kaplan-Meier analysis suggested a significantly elevated risk of all-cause death (log-rank P< 0.001) in patients with higher SII, especially during the short-term follow-up period of 21 days. Conclusion: SII is closely linked to an elevated risk of RF and death in COPD patients. It appears to be a potential predictor of the prognosis of COPD patients, which is helpful for the risk stratification of this population. However, more prospective studies are warranted to consolidate our conclusion. Keywords: systemic immune-inflammation index, chronic obstructive pulmonary disease, respiratory failure, mortality, MIMIC-IV database Chronic obstructive pulmonary disease (COPD) is a prevalent long-lasting airway inflammatory condition that features enduring respiratory symptoms and irreversible airflow restriction. 1,2 Globally, COPD ranks third in terms of cause of death behind ischemic heart disease and cerebrovascular disease, owing to high morbidity and mortality rates. 3,4 Respiratory failure (RF), especially hypercapnic RF (HRF), frequently occurs in most COPD patients at severe or end-stage. 5,6 COPD complicated by RF (COPD+RF) increases the difficulty of treatment, resulting in poor prognosis. 7 COPD+RF patients usually require unplanned hospitalization or intensive care unit (ICU). The short-term mortality reaches nearly 30%, 8–10 and the mortality of critically ill patients who need mechanical ventilation is as high as 50%. 11,12 This undoubtedly has a huge negative influence on patients' health, economy, and quality of life. Therefore, early identification of the risk of RF in COPD patients is of significant importance. Exploring an easily accessible biomarker related to the incidence of RF to predict the clinical outcome can assist clinicians in determining high-risk patients early and implementing preventative strategies. Despite the elusive pathogenesis of RF in COPD, aberrant immune activation and systemic inflammation constitute key contributors. 13,14 The systemic immune-inflammation index (SII) is a comprehensive inflammatory indicator that is computed by peripheral lymphocyte, neutrophil, and platelet counts. Neutrophils, platelets, and produced cytokines are mostly tied to nonspecific immune responses. 14–17 In contrast, lymphocytes are primarily linked to immune-related pathways. 14–17 SII is more stable and can more accurately reflect the inflammation state of the human body than the absolute count of a single immune cell. 18,19 In addition -Abstract Truncated-

Aggregate index of systemic inflammation (AISI) in admission as a reliable predictor of mortality in COPD patients with COVID-19

The aggregate index of systemic inflammation may predict mortality in COVID-19 patients with chronic renal failure

Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients

Systemic Immune-Inflammatory Index predicts prognosis of patients with COVID-19: a retrospective study

The Aggregate Index of Systemic Inflammation as a Predictor of Mortality in Stroke Patients

Prognostic value of ANDC score and CRP-derived inflammatory markers in hospitalized adult patients with COVID-19

Inflammation/Coagulopathy/Immunology Responsive Index Predicts Poor COVID-19 Prognosis

Prognostic potential of neutrophil-to-lymphocyte ratio, platelet to lymphocyte ratio, and monocyte to lymphocyte ratio in acute myocardial infarction patients combined with chronic obstructive pulmonary disease

Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19: a retrospective study

Relationship Between Systemic Immune-Inflammation Index and Risk of Respiratory Failure and Death in COPD: A Retrospective Cohort Study Based on the MIMIC-IV Database

Association of inflammatory biomarker abnormalities with mortality in COVID-19: a meta-analysis

Optimizing inhaled corticosteroid use in patients with chronic obstructive pulmonary disease: assessing blood eosinophils, neutrophil-to-lymphocyte ratio, and mortality outcomes in US adults

A novel nutritional inflammation index for predicting mortality in acute ischemic stroke patients: insights into advanced lung cancer inflammation index from the Medical Information Mart for Intensive Care-IV database

CRP, Fibrinogen, White Blood Cells, and Blood Cell Indices as Prognostic Biomarkers of Future COPD Exacerbation Frequency: The TIE Cohort Study

Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia

Association of Blood Inflammatory Biomarkers with Clinical Outcomes in Patients with AECOPD: An 8-Year Retrospective Study in Beijing

The Role of Aspartate Aminotransferase-to-Lymphocyte Ratio Index (ALRI) in Predicting Mortality in SARS-CoV-2 Infection

An inflammatory cytokine signature predicts COVID-19 severity and survival

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Association between systemic immune-inflammation index and chronic obstructive pulmonary disease: a population-based study

The Role of IL-6/lymphocyte Ratio in the Peripheral Blood of Severe Patients with COVID-19.